Global Ropivacaine Mesylate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ropivacaine Mesylate Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup.
Ropivacaine Mesylate report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ropivacaine Mesylate market is projected to reach US$ 1973.3 million in 2029, increasing from US$ 870 million in 2022, with the CAGR of 6.4% during the period of 2024 to 2029. Demand from Surgical Anesthesia and Major Nerve Block are the major drivers for the industry.
Anesthetics are an indispensable class of important chemical substances in modern clinical surgery. The mechanism of action is to inhibit and block the conduction of nerve impulses. It plays an important role in alleviating the pain of patients and promoting the development of surgical medicine. With the development of medicine, more attention is paid to the patient's somatosensory, and the increase of painless surgery has promoted this market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ropivacaine Mesylate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Akorn
Anant Pharmaceuticals
SGPharma
Nephron Pharmaceuticals
Sintetica SA
AstraZeneca
Manus Aktteva Biopharma LLP
Zhejiang Xianju Pharmaceutical Co.,Ltd
Jiangsu Nhwa Pharmaceutical Co.,Ltd.
Yangzi River Pharmaceutical Group
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co.,Ltd
Segment by Type
2 mg/mL (0.2%)
5 mg/mL (0.5%)
7.5 mg/mL (0.75%)
10 mg/mL (1%)
Surgical Anesthesia
Major Nerve Block
Acute Pain Management
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ropivacaine Mesylate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ropivacaine Mesylate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ropivacaine Mesylate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Ropivacaine Mesylate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ropivacaine Mesylate introduction, etc. Ropivacaine Mesylate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ropivacaine Mesylate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Ropivacaine Mesylate report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ropivacaine Mesylate market is projected to reach US$ 1973.3 million in 2029, increasing from US$ 870 million in 2022, with the CAGR of 6.4% during the period of 2024 to 2029. Demand from Surgical Anesthesia and Major Nerve Block are the major drivers for the industry.
Anesthetics are an indispensable class of important chemical substances in modern clinical surgery. The mechanism of action is to inhibit and block the conduction of nerve impulses. It plays an important role in alleviating the pain of patients and promoting the development of surgical medicine. With the development of medicine, more attention is paid to the patient's somatosensory, and the increase of painless surgery has promoted this market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ropivacaine Mesylate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Akorn
Anant Pharmaceuticals
SGPharma
Nephron Pharmaceuticals
Sintetica SA
AstraZeneca
Manus Aktteva Biopharma LLP
Zhejiang Xianju Pharmaceutical Co.,Ltd
Jiangsu Nhwa Pharmaceutical Co.,Ltd.
Yangzi River Pharmaceutical Group
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co.,Ltd
Segment by Type
2 mg/mL (0.2%)
5 mg/mL (0.5%)
7.5 mg/mL (0.75%)
10 mg/mL (1%)
Segment by Application
Surgical Anesthesia
Major Nerve Block
Acute Pain Management
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ropivacaine Mesylate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ropivacaine Mesylate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ropivacaine Mesylate industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Ropivacaine Mesylate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ropivacaine Mesylate introduction, etc. Ropivacaine Mesylate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ropivacaine Mesylate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices